User Defined ID,Accession,Visit,Study Identifier,Study Part,Cohort Group,Treatment,Date of Informed Consent,Date of Screening Visit,Day of Screening,Date of T1DM Diagnosis,Day of Diagnosis of T1DM,Day 0 Date,Enrolled,Enrollment Date,Safety Sample,Intent to Treat Sample,Analysis Sample,Date of First Low Dose Infusion,Date of First High Dose Infusion,Date of Last Low Dose Infusion,Date of Last High Dose Infusion,Date of Last Follow-up,Date of Primary Endpoint Visit,Day of Last Follow-up,Completed Study (including follow-up),Study Status,Date of Study Termination/Completion,Day of Study Termination,Terminated Study Reason,Completed Study Drug,Date of Study Drug Discont./Completion,Day of Study Drug Discont./Completion,Discontinued Therapy Reason,Age (years),Sex (Char),Baseline Height (cm),Baseline Weight (kg),Baseline BMI (kg/m^2),Race,Race.1,Ethnicity,Status,Phase,Visit Sequence Number,Visit Number,Visit.1,C-peptide Test Date,C-peptide Test Study Day,Boost Dose Start Time,Boost Dose End Time,Timepoint,Time of C-peptide Sample- Character,Time of C-peptide Sample- Numeric,Actual Time Point of Sample- Minutes,C-peptide Result- reported,C-peptide Result- standardized,C-peptide Test Reported Character Result,C-peptide Result Units - reported,C-peptide Result Units - standardized,Reference Range,Flag,Data Snapshot Date,Number of Low Dose Infusions,Number of High Dose Infusions
RETAIN_135342,SUB228868,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-04-18,-16.0,09:10,09:12,-10.0,09:00,32400.0,-10.0,1.48,0.48988,1.48,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-04-18,-16.0,09:10,09:12,0.0,09:10,33000.0,0.0,1.49,0.49319,1.49,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-04-18,-16.0,09:10,09:12,15.0,09:25,33900.0,13.0,1.66,0.54946,1.66,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-04-18,-16.0,09:10,09:12,30.0,09:40,34800.0,28.0,2.14,0.70834,2.14,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-04-18,-16.0,09:10,09:12,60.0,10:10,36600.0,58.0,4.2,1.3902,4.20,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-04-18,-16.0,09:10,09:12,90.0,10:40,38400.0,88.0,3.54,1.17174,3.54,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-04-18,-16.0,09:10,09:12,120.0,11:10,40200.0,118.0,3.04,1.00624,3.04,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-04-18,-16.0,09:10,09:12,150.0,11:40,42000.0,148.0,2.89,0.95659,2.89,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-04-18,-16.0,09:10,09:12,180.0,12:10,43800.0,178.0,2.8,0.9268,2.80,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-04-18,-16.0,09:10,09:12,210.0,12:40,45600.0,208.0,2.51,0.83081,2.51,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-04-18,-16.0,09:10,09:12,240.0,13:10,47400.0,238.0,1.81,0.59911,1.81,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2010-11-14,194.0,08:50,08:50,90.0,10:20,37200.0,90.0,3.64,1.20484,3.64,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2010-11-14,194.0,08:50,08:50,120.0,10:50,39000.0,120.0,3.39,1.12209,3.39,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-05-01,362.0,09:30,09:31,30.0,10:00,36000.0,29.0,3.84,1.27104,3.84,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-05-01,362.0,09:30,09:31,60.0,10:30,37800.0,59.0,4.99,1.65169,4.99,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-05-01,362.0,09:30,09:31,90.0,11:00,39600.0,89.0,5.32,1.76092,5.32,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-05-01,362.0,09:30,09:31,120.0,11:30,41400.0,119.0,3.92,1.29752,3.92,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-05-01,362.0,09:30,09:31,150.0,12:00,43200.0,149.0,3.38,1.11878,3.38,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-05-01,362.0,09:30,09:31,180.0,12:30,45000.0,179.0,2.64,0.87384,2.64,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-05-01,362.0,09:30,09:31,210.0,13:00,46800.0,209.0,1.99,0.65869,1.99,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-05-01,362.0,09:30,09:31,240.0,13:30,48600.0,239.0,1.36,0.45016,1.36,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-04-29,726.0,08:50,08:53,-10.0,08:39,31140.0,-11.0,1.06,0.35086,1.06,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-04-29,726.0,08:50,08:53,0.0,08:49,31740.0,-1.0,1.1,0.3641,1.10,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-05-01,362.0,09:30,09:31,-10.0,09:20,33600.0,-10.0,1.32,0.43692,1.32,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-05-01,362.0,09:30,09:31,0.0,09:30,34200.0,0.0,1.39,0.46009,1.39,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-05-01,362.0,09:30,09:31,15.0,09:45,35100.0,14.0,2.41,0.79771,2.41,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2010-08-31,119.0,07:40,07:40,-10.0,07:30,27000.0,-10.0,1.48,0.48988,1.48,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2010-08-31,119.0,07:40,07:40,0.0,07:40,27600.0,0.0,1.38,0.45678,1.38,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2010-08-31,119.0,07:40,07:40,15.0,07:55,28500.0,15.0,1.62,0.53622,1.62,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2010-08-31,119.0,07:40,07:40,30.0,08:10,29400.0,30.0,3.11,1.02941,3.11,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2010-08-31,119.0,07:40,07:40,60.0,08:40,31200.0,60.0,3.16,1.04596,3.16,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2010-08-31,119.0,07:40,07:40,90.0,09:10,33000.0,90.0,2.95,0.97645,2.95,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2010-08-31,119.0,07:40,07:40,120.0,09:40,34800.0,120.0,2.81,0.93011,2.81,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2010-11-14,194.0,08:50,08:50,-10.0,08:40,31200.0,-10.0,1.7,0.5627,1.70,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2010-11-14,194.0,08:50,08:50,0.0,08:50,31800.0,0.0,1.64,0.54284,1.64,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2010-11-14,194.0,08:50,08:50,15.0,09:05,32700.0,15.0,2.14,0.70834,2.14,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-04-29,726.0,08:50,08:53,15.0,09:05,32700.0,12.0,1.32,0.43692,1.32,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-04-29,726.0,08:50,08:53,30.0,09:20,33600.0,27.0,2.09,0.69179,2.09,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-04-29,726.0,08:50,08:53,60.0,09:50,35400.0,57.0,3.23,1.06913,3.23,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-04-29,726.0,08:50,08:53,180.0,11:50,42600.0,177.0,3.18,1.05258,3.18,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-04-29,726.0,08:50,08:53,90.0,10:20,37200.0,87.0,2.89,0.95659,2.89,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-04-29,726.0,08:50,08:53,120.0,10:50,39000.0,117.0,3.42,1.13202,3.42,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-04-29,726.0,08:50,08:53,150.0,11:20,40800.0,147.0,3.75,1.24125,3.75,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-04-29,726.0,08:50,08:53,210.0,12:20,44400.0,207.0,2.48,0.82088,2.48,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-04-29,726.0,08:50,08:53,240.0,12:50,46200.0,237.0,2.19,0.72489,2.19,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2010-11-14,194.0,08:50,08:50,60.0,09:50,35400.0,60.0,5.46,1.80726,5.46,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_135342,SUB228868,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-04-17,2010-04-18,-16.0,2010-03-31,-34.0,2010-05-04,Yes,2010-05-04,Yes,Yes,E/I/S,2010-05-04,2010-07-06,2010-06-08,2010-08-10,2012-04-29,2011-05-01,726.0,Yes,Complete,2012-04-29,726.0,,Yes,2010-08-10,98.0,,16.0,Female,168.9,69.2,24.257542185,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2010-11-14,194.0,08:50,08:50,30.0,09:20,33600.0,30.0,3.79,1.25449,3.79,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-01-28,-26.0,09:00,09:01,15.0,09:15,33300.0,14.0,1.22,0.40382,1.22,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-01-28,-26.0,09:00,09:01,240.0,13:00,46800.0,239.0,2.37,0.78447,2.37,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-16,358.0,09:23,09:26,240.0,13:23,48180.0,237.0,0.37,0.12247,0.37,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-01-28,-26.0,09:00,09:01,210.0,12:30,45000.0,209.0,2.68,0.88708,2.68,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-01-28,-26.0,09:00,09:01,-10.0,08:50,31800.0,-10.0,1.17,0.38727,1.17,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-01-28,-26.0,09:00,09:01,0.0,09:00,32400.0,0.0,1.19,0.39389,1.19,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-01-28,-26.0,09:00,09:01,30.0,09:30,34200.0,29.0,1.24,0.41044,1.24,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-01-28,-26.0,09:00,09:01,60.0,10:00,36000.0,59.0,1.58,0.52298,1.58,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-01-28,-26.0,09:00,09:01,90.0,10:30,37800.0,89.0,2.2,0.7282,2.20,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-01-28,-26.0,09:00,09:01,120.0,11:00,39600.0,119.0,2.27,0.75137,2.27,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-01-28,-26.0,09:00,09:01,150.0,11:30,41400.0,149.0,3.08,1.01948,3.08,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-01-28,-26.0,09:00,09:01,180.0,12:00,43200.0,179.0,2.89,0.95659,2.89,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-09-28,217.0,10:05,10:06,120.0,12:05,43500.0,119.0,0.6,0.1986,0.60,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-16,358.0,09:23,09:26,180.0,12:23,44580.0,177.0,0.5,0.1655,0.50,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-16,358.0,09:23,09:26,210.0,12:53,46380.0,207.0,0.4,0.1324,0.40,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-07-06,133.0,09:30,09:31,30.0,10:00,36000.0,29.0,0.9,0.2979,0.90,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-07-06,133.0,09:30,09:31,60.0,10:30,37800.0,59.0,1.52,0.50312,1.52,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-07-06,133.0,09:30,09:31,90.0,11:00,39600.0,89.0,1.41,0.46671,1.41,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-07-06,133.0,09:30,09:31,120.0,11:30,41400.0,119.0,1.44,0.47664,1.44,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-09-28,217.0,10:05,10:06,-10.0,09:55,35700.0,-10.0,0.27,0.08937,0.27,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_143437,SUB228869,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-09-28,217.0,10:05,10:06,0.0,10:05,36300.0,0.0,0.27,0.08937,0.27,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_143437,SUB228869,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-09-28,217.0,10:05,10:06,15.0,10:20,37200.0,14.0,0.32,0.10592,0.32,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-09-28,217.0,10:05,10:06,30.0,10:35,38100.0,29.0,0.53,0.17543,0.53,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-09-28,217.0,10:05,10:06,60.0,11:05,39900.0,59.0,0.68,0.22508,0.68,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-09-28,217.0,10:05,10:06,90.0,11:35,41700.0,89.0,0.64,0.21184,0.64,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-07-06,133.0,09:30,09:31,-10.0,09:20,33600.0,-10.0,0.79,0.26149,0.79,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-07-06,133.0,09:30,09:31,0.0,09:30,34200.0,0.0,0.79,0.26149,0.79,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-07-06,133.0,09:30,09:31,15.0,09:45,35100.0,14.0,0.85,0.28135,0.85,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-03,739.0,09:30,09:32,30.0,10:00,36000.0,28.0,0.07,0.02317,0.07,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-03,739.0,09:30,09:32,60.0,10:30,37800.0,58.0,0.17,0.05627,0.17,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-03,739.0,09:30,09:32,90.0,11:00,39600.0,88.0,0.16,0.05296,0.16,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-03,739.0,09:30,09:32,120.0,11:30,41400.0,118.0,0.16,0.05296,0.16,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-03,739.0,09:30,09:32,150.0,12:00,43200.0,148.0,0.12,0.03972,0.12,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-03,739.0,09:30,09:32,180.0,12:30,45000.0,178.0,0.11,0.03641,0.11,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-03,739.0,09:30,09:32,210.0,13:00,46800.0,208.0,0.09,0.02979,0.09,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-03,739.0,09:30,09:32,240.0,13:30,48600.0,238.0,0.1,0.0331,0.10,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-16,358.0,09:23,09:26,30.0,09:53,35580.0,27.0,0.36,0.11916,0.36,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-16,358.0,09:23,09:26,60.0,10:23,37380.0,57.0,0.48,0.15888,0.48,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-03,739.0,09:30,09:32,-10.0,09:20,33600.0,-10.0,0.05,0.01655,0.05,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_143437,SUB228869,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-03,739.0,09:30,09:32,0.0,09:30,34200.0,0.0,0.05,0.01655,0.05,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_143437,SUB228869,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-03,739.0,09:30,09:32,15.0,09:45,35100.0,13.0,0.06,0.01986,0.06,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-16,358.0,09:23,09:26,15.0,09:38,34680.0,12.0,0.26,0.08606,0.26,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-16,358.0,09:23,09:26,-10.0,09:13,33180.0,-10.0,0.26,0.08606,0.26,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_143437,SUB228869,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-16,358.0,09:23,09:26,0.0,09:23,33780.0,0.0,0.27,0.08937,0.27,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_143437,SUB228869,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-16,358.0,09:23,09:26,150.0,11:53,42780.0,147.0,0.42,0.13902,0.42,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-16,358.0,09:23,09:26,90.0,10:53,39180.0,87.0,0.46,0.15226,0.46,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_143437,SUB228869,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-01-22,2011-01-28,-26.0,2010-11-18,-97.0,2011-02-23,Yes,2011-02-23,Yes,Yes,E/I/S,2011-02-23,2011-05-11,2011-03-30,2011-06-15,2013-02-21,2012-02-16,729.0,Yes,Complete,2013-02-21,729.0,,Yes,2011-06-15,112.0,,9.0,Female,137.5,35.7,18.882644628,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-16,358.0,09:23,09:26,120.0,11:23,40980.0,117.0,0.47,0.15557,0.47,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-7.0,09:05,09:08,0.0,09:00,32400.0,-5.0,0.16,0.05296,0.16,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_168164,SUB228870,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-7.0,09:05,09:08,90.0,10:38,38280.0,90.0,0.78,0.25818,0.78,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-7.0,09:05,09:08,-10.0,08:50,31800.0,-15.0,0.15,0.04965,0.15,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_168164,SUB228870,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-7.0,09:05,09:08,210.0,12:38,45480.0,210.0,0.72,0.23832,0.72,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-7.0,09:05,09:08,15.0,09:23,33780.0,15.0,0.28,0.09268,0.28,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-7.0,09:05,09:08,30.0,09:38,34680.0,30.0,0.34,0.11254,0.34,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-7.0,09:05,09:08,60.0,10:08,36480.0,60.0,0.53,0.17543,0.53,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-07,730.0,08:38,08:40,90.0,10:10,36600.0,90.0,0.31,0.10261,0.31,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-07,730.0,08:38,08:40,120.0,10:42,38520.0,122.0,0.35,0.11585,0.35,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-07,730.0,08:38,08:40,150.0,11:14,40440.0,154.0,0.33,0.10923,0.33,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-07,730.0,08:38,08:40,180.0,11:40,42000.0,180.0,0.31,0.10261,0.31,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-07,730.0,08:38,08:40,210.0,12:10,43800.0,210.0,0.28,0.09268,0.28,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-07,730.0,08:38,08:40,240.0,12:40,45600.0,240.0,0.13,0.04303,0.13,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-7.0,09:05,09:08,120.0,11:08,40080.0,120.0,0.97,0.32107,0.97,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-7.0,09:05,09:08,150.0,11:38,41880.0,150.0,0.96,0.31776,0.96,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-7.0,09:05,09:08,180.0,12:08,43680.0,180.0,0.94,0.31114,0.94,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-07-06,120.0,07:40,07:44,60.0,08:40,31200.0,56.0,0.63,0.20853,0.63,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-07-06,120.0,07:40,07:44,90.0,09:10,33000.0,86.0,0.78,0.25818,0.78,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-07-06,120.0,07:40,07:44,120.0,09:40,34800.0,116.0,0.89,0.29459,0.89,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-7.0,09:05,09:08,240.0,13:08,47280.0,240.0,0.57,0.18867,0.57,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-28,357.0,08:13,08:15,90.0,09:45,35100.0,90.0,0.81,0.26811,0.81,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-28,357.0,08:13,08:15,120.0,10:15,36900.0,120.0,0.77,0.25487,0.77,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-28,357.0,08:13,08:15,150.0,10:45,38700.0,150.0,0.81,0.26811,0.81,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-28,357.0,08:13,08:15,180.0,11:15,40500.0,180.0,0.62,0.20522,0.62,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-28,357.0,08:13,08:15,210.0,11:45,42300.0,210.0,0.55,0.18205,0.55,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-28,357.0,08:13,08:15,240.0,12:15,44100.0,240.0,0.47,0.15557,0.47,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-07-06,120.0,07:40,07:44,0.0,07:35,27300.0,-5.0,0.15,0.04965,0.15,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_168164,SUB228870,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-07-06,120.0,07:40,07:44,15.0,07:55,28500.0,11.0,0.24,0.07944,0.24,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-07-06,120.0,07:40,07:44,30.0,08:10,29400.0,26.0,0.42,0.13902,0.42,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-28,357.0,08:13,08:15,0.0,08:10,29400.0,-3.0,0.11,0.03641,0.11,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_168164,SUB228870,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-28,357.0,08:13,08:15,15.0,08:30,30600.0,15.0,0.19,0.06289,0.19,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-28,357.0,08:13,08:15,30.0,08:45,31500.0,30.0,0.33,0.10923,0.33,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-28,357.0,08:13,08:15,60.0,09:15,33300.0,60.0,0.57,0.18867,0.57,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-07,730.0,08:38,08:40,60.0,09:40,34800.0,60.0,0.29,0.09599,0.29,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-09-20,196.0,07:35,07:36,-10.0,07:25,26700.0,-10.0,0.52,0.17212,0.52,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-09-20,196.0,07:35,07:36,0.0,07:35,27300.0,0.0,0.43,0.14233,0.43,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_168164,SUB228870,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-09-20,196.0,07:35,07:36,15.0,07:50,28200.0,14.0,0.51,0.16881,0.51,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-09-20,196.0,07:35,07:36,30.0,08:05,29100.0,29.0,0.57,0.18867,0.57,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-09-20,196.0,07:35,07:36,60.0,08:35,30900.0,59.0,0.63,0.20853,0.63,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-07-06,120.0,07:40,07:44,-10.0,07:25,26700.0,-15.0,0.14,0.04634,0.14,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_168164,SUB228870,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-09-20,196.0,07:35,07:36,120.0,09:35,34500.0,119.0,0.63,0.20853,0.63,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-02-28,357.0,08:13,08:15,-10.0,08:00,28800.0,-13.0,0.11,0.03641,0.11,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_168164,SUB228870,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-07,730.0,08:38,08:40,-10.0,08:25,30300.0,-13.0,0.18,0.05958,0.18,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_168164,SUB228870,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-07,730.0,08:38,08:40,0.0,08:35,30900.0,-3.0,0.16,0.05296,0.16,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_168164,SUB228870,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-07,730.0,08:38,08:40,15.0,08:55,32100.0,15.0,0.19,0.06289,0.19,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-03-07,730.0,08:38,08:40,30.0,09:10,33000.0,30.0,0.23,0.07613,0.23,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_168164,SUB228870,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-7.0,2010-12-20,-78.0,2011-03-08,Yes,2011-03-08,Yes,Yes,E/I/S,2011-03-08,2011-05-12,2011-04-12,2011-06-16,2013-03-07,2012-02-28,730.0,Yes,Complete,2013-03-07,730.0,,Yes,2011-06-16,100.0,,11.0,Male,151.0,35.9,15.744923468,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-09-20,196.0,07:35,07:36,90.0,09:05,32700.0,89.0,0.59,0.19529,0.59,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-05,722.0,00:00,00:00,150.0,,,,0.65,0.21515,0.65,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-05,722.0,00:00,00:00,180.0,,,,0.62,0.20522,0.62,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-05,722.0,00:00,00:00,210.0,,,,0.58,0.19198,0.58,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-30,-15.0,09:10,09:15,60.0,10:10,36600.0,55.0,1.85,0.61235,1.85,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-30,-15.0,09:10,09:15,90.0,10:40,38400.0,85.0,1.98,0.65538,1.98,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-30,-15.0,09:10,09:15,120.0,11:10,40200.0,115.0,1.85,0.61235,1.85,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-05,722.0,00:00,00:00,240.0,,,,0.42,0.13902,0.42,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-05,722.0,00:00,00:00,0.0,,,,0.24,0.07944,0.24,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_192151,SUB228871,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-05,722.0,00:00,00:00,15.0,,,,0.41,0.13571,0.41,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-05,722.0,00:00,00:00,30.0,,,,0.55,0.18205,0.55,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-05,722.0,00:00,00:00,60.0,,,,0.61,0.20191,0.61,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-05,722.0,00:00,00:00,90.0,,,,0.65,0.21515,0.65,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-05,722.0,00:00,00:00,120.0,,,,0.69,0.22839,0.69,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-30,-15.0,09:10,09:15,-10.0,09:00,32400.0,-10.0,0.15,0.04965,0.15,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_192151,SUB228871,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-30,-15.0,09:10,09:15,0.0,09:10,33000.0,0.0,0.13,0.04303,0.13,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_192151,SUB228871,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-30,-15.0,09:10,09:15,15.0,09:25,33900.0,10.0,0.79,0.26149,0.79,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-30,-15.0,09:10,09:15,30.0,09:40,34800.0,25.0,1.32,0.43692,1.32,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2017,000,PIV17,Visit 17/Week 52,2012-01-11,362.0,08:40,08:43,120.0,10:43,38580.0,120.0,1.46,0.48326,1.46,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2017,000,PIV17,Visit 17/Week 52,2012-01-11,362.0,08:40,08:43,150.0,11:13,40380.0,150.0,1.38,0.45678,1.38,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-30,-15.0,09:10,09:15,150.0,11:40,42000.0,145.0,1.58,0.52298,1.58,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2017,000,PIV17,Visit 17/Week 52,2012-01-11,362.0,08:40,08:43,210.0,12:13,43980.0,210.0,1.35,0.44685,1.35,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2017,000,PIV17,Visit 17/Week 52,2012-01-11,362.0,08:40,08:43,240.0,12:43,45780.0,240.0,1.2,0.3972,1.20,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-30,-15.0,09:10,09:15,180.0,12:10,43800.0,175.0,1.16,0.38396,1.16,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-30,-15.0,09:10,09:15,210.0,12:40,45600.0,205.0,0.77,0.25487,0.77,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-30,-15.0,09:10,09:15,240.0,13:10,47400.0,235.0,0.63,0.20853,0.63,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-13,119.0,08:55,09:00,-10.0,08:45,31500.0,-10.0,0.57,0.18867,0.57,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-13,119.0,08:55,09:00,0.0,08:55,32100.0,0.0,0.44,0.14564,0.44,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_192151,SUB228871,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-13,119.0,08:55,09:00,15.0,09:10,33000.0,10.0,0.67,0.22177,0.67,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-13,119.0,08:55,09:00,30.0,09:25,33900.0,25.0,1.37,0.45347,1.37,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-13,119.0,08:55,09:00,60.0,09:55,35700.0,55.0,2.15,0.71165,2.15,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-13,119.0,08:55,09:00,90.0,10:25,37500.0,85.0,1.94,0.64214,1.94,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-13,119.0,08:55,09:00,120.0,10:55,39300.0,115.0,2.94,0.97314,2.94,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2017,000,PIV17,Visit 17/Week 52,2012-01-11,362.0,08:40,08:43,180.0,11:43,42180.0,180.0,1.41,0.46671,1.41,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-05,722.0,00:00,00:00,-10.0,,,,0.23,0.07613,0.23,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_192151,SUB228871,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-29,196.0,09:38,09:41,-10.0,09:28,34080.0,-10.0,0.87,0.28797,0.87,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-29,196.0,09:38,09:41,0.0,09:38,34680.0,0.0,0.87,0.28797,0.87,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-29,196.0,09:38,09:41,15.0,09:53,35580.0,12.0,1.42,0.47002,1.42,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-29,196.0,09:38,09:41,30.0,10:08,36480.0,27.0,2.0,0.662,2.00,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-29,196.0,09:38,09:41,60.0,10:38,38280.0,57.0,1.98,0.65538,1.98,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-29,196.0,09:38,09:41,90.0,11:08,40080.0,87.0,2.53,0.83743,2.53,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-29,196.0,09:38,09:41,120.0,11:38,41880.0,117.0,2.68,0.88708,2.68,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2017,000,PIV17,Visit 17/Week 52,2012-01-11,362.0,08:40,08:43,30.0,09:13,33180.0,30.0,1.43,0.47333,1.43,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2017,000,PIV17,Visit 17/Week 52,2012-01-11,362.0,08:40,08:43,60.0,09:43,34980.0,60.0,1.71,0.56601,1.71,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2017,000,PIV17,Visit 17/Week 52,2012-01-11,362.0,08:40,08:43,90.0,10:13,36780.0,90.0,1.38,0.45678,1.38,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2017,000,PIV17,Visit 17/Week 52,2012-01-11,362.0,08:40,08:43,-10.0,08:30,30600.0,-10.0,1.15,0.38065,1.15,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2017,000,PIV17,Visit 17/Week 52,2012-01-11,362.0,08:40,08:43,0.0,08:40,31200.0,0.0,1.08,0.35748,1.08,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_192151,SUB228871,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-12-30,2010-12-30,-15.0,2010-10-10,-96.0,2011-01-14,Yes,2011-01-14,Yes,Yes,E/I/S,2011-01-14,,2011-01-21,,2013-01-11,2012-01-11,728.0,No,Terminated early from protocol,2013-01-11,728.0,Investigator Decision,No,2011-01-21,7.0,Investigator Decision,16.0,Male,,72.0,23.781212842,Black or African American,Black or African American,Not Hispanic or Latino,Terminated from study, Discontinued therapy,2017,000,PIV17,Visit 17/Week 52,2012-01-11,362.0,08:40,08:43,15.0,08:58,32280.0,15.0,1.22,0.40382,1.22,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-04,120.0,08:50,08:55,30.0,09:20,33600.0,25.0,3.31,1.09561,3.31,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-04,120.0,08:50,08:55,-10.0,08:40,31200.0,-10.0,1.59,0.52629,1.59,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-04,120.0,08:50,08:55,0.0,08:50,31800.0,0.0,1.62,0.53622,1.62,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-04,120.0,08:50,08:55,15.0,09:05,32700.0,10.0,2.2,0.7282,2.20,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-11,738.0,08:10,08:14,180.0,11:10,40200.0,176.0,0.48,0.15888,0.48,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-04,120.0,08:50,08:55,60.0,09:50,35400.0,55.0,3.88,1.28428,3.88,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-04,120.0,08:50,08:55,90.0,10:20,37200.0,85.0,3.86,1.27766,3.86,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-04,120.0,08:50,08:55,120.0,10:50,39000.0,115.0,4.56,1.50936,4.56,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-17,-18.0,09:35,09:37,60.0,10:35,38100.0,58.0,4.48,1.48288,4.48,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-17,-18.0,09:35,09:37,90.0,11:05,39900.0,88.0,3.87,1.28097,3.87,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-11,738.0,08:10,08:14,-10.0,08:00,28800.0,-10.0,0.12,0.03972,0.12,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_215465,SUB228872,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-11,738.0,08:10,08:14,0.0,08:10,29400.0,0.0,0.11,0.03641,0.11,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_215465,SUB228872,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-11,738.0,08:10,08:14,15.0,08:25,30300.0,11.0,0.17,0.05627,0.17,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-11,738.0,08:10,08:14,30.0,08:40,31200.0,26.0,0.2,0.0662,0.20,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-11,738.0,08:10,08:14,60.0,09:10,33000.0,56.0,0.41,0.13571,0.41,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-11,738.0,08:10,08:14,90.0,09:40,34800.0,86.0,0.44,0.14564,0.44,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-11,738.0,08:10,08:14,120.0,10:10,36600.0,116.0,0.51,0.16881,0.51,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-11,738.0,08:10,08:14,150.0,10:40,38400.0,146.0,0.6,0.1986,0.60,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-11,738.0,08:10,08:14,210.0,11:40,42000.0,206.0,0.28,0.09268,0.28,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-01-11,738.0,08:10,08:14,240.0,12:10,43800.0,236.0,0.17,0.05627,0.17,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-17,-18.0,09:35,09:37,30.0,10:05,36300.0,28.0,2.42,0.80102,2.42,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-28,358.0,09:20,09:23,0.0,09:20,33600.0,0.0,1.35,0.44685,1.35,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-28,358.0,09:20,09:23,15.0,09:35,34500.0,12.0,2.91,0.96321,2.91,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-28,358.0,09:20,09:23,30.0,09:50,35400.0,27.0,1.56,0.51636,1.56,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-17,-18.0,09:35,09:37,120.0,11:35,41700.0,118.0,4.95,1.63845,4.95,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-17,-18.0,09:35,09:37,150.0,12:05,43500.0,148.0,5.03,1.66493,5.03,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-17,-18.0,09:35,09:37,180.0,12:35,45300.0,178.0,3.29,1.08899,3.29,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-17,-18.0,09:35,09:37,210.0,13:05,47100.0,208.0,3.07,1.01617,3.07,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-17,-18.0,09:35,09:37,240.0,13:20,48000.0,223.0,2.48,0.82088,2.48,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-28,358.0,09:20,09:23,210.0,12:50,46200.0,207.0,1.82,0.60242,1.82,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-28,358.0,09:20,09:23,240.0,13:20,48000.0,237.0,1.65,0.54615,1.65,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-17,-18.0,09:35,09:37,-10.0,09:30,34200.0,-5.0,1.27,0.42037,1.27,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-17,-18.0,09:35,09:37,0.0,09:35,34500.0,0.0,1.23,0.40713,1.23,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-12-17,-18.0,09:35,09:37,15.0,09:50,35400.0,13.0,1.29,0.42699,1.29,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-22,199.0,09:17,09:18,-10.0,09:05,32700.0,-12.0,0.8,0.2648,0.80,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-22,199.0,09:17,09:18,0.0,09:17,33420.0,0.0,0.78,0.25818,0.78,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-22,199.0,09:17,09:18,15.0,09:32,34320.0,14.0,1.14,0.37734,1.14,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-28,358.0,09:20,09:23,60.0,10:20,37200.0,57.0,3.03,1.00293,3.03,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-28,358.0,09:20,09:23,90.0,10:50,39000.0,87.0,2.8,0.9268,2.80,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-28,358.0,09:20,09:23,120.0,11:20,40800.0,117.0,2.79,0.92349,2.79,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-28,358.0,09:20,09:23,150.0,11:50,42600.0,147.0,2.72,0.90032,2.72,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-28,358.0,09:20,09:23,180.0,12:20,44400.0,177.0,2.29,0.75799,2.29,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-28,358.0,09:20,09:23,-10.0,09:10,33000.0,-10.0,1.38,0.45678,1.38,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-22,199.0,09:17,09:18,60.0,10:17,37020.0,59.0,3.4,1.1254,3.40,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-22,199.0,09:17,09:18,90.0,10:47,38820.0,89.0,3.79,1.25449,3.79,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-22,199.0,09:17,09:18,120.0,11:17,40620.0,119.0,4.56,1.50936,4.56,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_215465,SUB228872,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-12-17,2010-12-17,-18.0,2010-10-02,-94.0,2011-01-04,Yes,2011-01-04,Yes,Yes,E/I/S,2011-01-04,2011-03-09,2011-02-08,2011-04-13,2013-01-11,2011-12-28,738.0,Yes,Complete,2013-01-11,738.0,,Yes,2011-04-18,104.0,,9.0,Female,143.8,37.2,17.989751645,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-22,199.0,09:17,09:18,30.0,09:47,35220.0,29.0,2.0,0.662,2.00,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-15,367.0,08:00,08:02,180.0,11:00,39600.0,178.0,0.55,0.18205,0.55,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-15,367.0,08:00,08:02,210.0,11:30,41400.0,208.0,0.49,0.16219,0.49,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-15,367.0,08:00,08:02,240.0,12:00,43200.0,238.0,0.38,0.12578,0.38,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-15,367.0,08:00,08:02,150.0,10:30,37800.0,148.0,0.53,0.17543,0.53,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-02-16,126.0,08:55,09:00,60.0,09:55,35700.0,55.0,1.82,0.60242,1.82,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-02-16,126.0,08:55,09:00,90.0,10:25,37500.0,85.0,2.12,0.70172,2.12,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-02-16,126.0,08:55,09:00,120.0,10:55,39300.0,115.0,2.23,0.73813,2.23,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-05-06,205.0,09:40,09:45,-10.0,09:30,34200.0,-10.0,0.56,0.18536,0.56,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-05-06,205.0,09:40,09:45,0.0,09:40,34800.0,0.0,0.3,0.0993,0.30,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_300339,SUB228873,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-05-06,205.0,09:40,09:45,15.0,09:55,35700.0,10.0,0.59,0.19529,0.59,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-05-06,205.0,09:40,09:45,30.0,10:10,36600.0,25.0,1.08,0.35748,1.08,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-05-06,205.0,09:40,09:45,60.0,10:41,38460.0,56.0,1.07,0.35417,1.07,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-05-06,205.0,09:40,09:45,90.0,11:10,40200.0,85.0,1.06,0.35086,1.06,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-05-06,205.0,09:40,09:45,120.0,11:40,42000.0,115.0,0.99,0.32769,0.99,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-02-16,126.0,08:55,09:00,30.0,09:25,33900.0,25.0,1.33,0.44023,1.33,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-15,367.0,08:00,08:02,-10.0,07:50,28200.0,-10.0,0.12,0.03972,0.12,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_300339,SUB228873,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-15,367.0,08:00,08:02,0.0,08:00,28800.0,0.0,0.12,0.03972,0.12,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_300339,SUB228873,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-15,367.0,08:00,08:02,15.0,08:15,29700.0,13.0,0.16,0.05296,0.16,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-15,367.0,08:00,08:02,30.0,08:30,30600.0,28.0,0.22,0.07282,0.22,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-15,367.0,08:00,08:02,60.0,09:00,32400.0,58.0,0.31,0.10261,0.31,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-15,367.0,08:00,08:02,90.0,09:30,34200.0,88.0,0.52,0.17212,0.52,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-15,367.0,08:00,08:02,120.0,10:00,36000.0,118.0,0.54,0.17874,0.54,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-10-05,-8.0,09:50,09:55,-10.0,09:40,34800.0,-10.0,0.82,0.27142,0.82,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-10-05,-8.0,09:50,09:55,0.0,09:50,35400.0,0.0,0.81,0.26811,0.81,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-10-05,-8.0,09:50,09:55,15.0,10:05,36300.0,10.0,0.79,0.26149,0.79,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-10-05,-8.0,09:50,09:55,30.0,10:20,37200.0,25.0,1.55,0.51305,1.55,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-10-05,-8.0,09:50,09:55,60.0,10:50,39000.0,55.0,1.96,0.64876,1.96,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-10-05,-8.0,09:50,09:55,90.0,11:20,40800.0,85.0,2.07,0.68517,2.07,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-10-05,-8.0,09:50,09:55,120.0,11:50,42600.0,115.0,2.2,0.7282,2.20,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-10-05,-8.0,09:50,09:55,150.0,12:20,44400.0,145.0,2.08,0.68848,2.08,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-10-05,-8.0,09:50,09:55,180.0,12:50,46200.0,175.0,2.47,0.81757,2.47,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-10-05,-8.0,09:50,09:55,210.0,13:20,48000.0,205.0,2.01,0.66531,2.01,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-10-05,-8.0,09:50,09:55,240.0,13:50,49800.0,235.0,1.88,0.62228,1.88,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-05,723.0,07:51,07:52,30.0,08:20,30000.0,28.0,0.09,0.02979,0.09,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-05,723.0,07:51,07:52,60.0,08:50,31800.0,58.0,0.17,0.05627,0.17,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-05,723.0,07:51,07:52,90.0,09:20,33600.0,88.0,0.18,0.05958,0.18,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-05,723.0,07:51,07:52,120.0,09:50,35400.0,118.0,0.17,0.05627,0.17,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-05,723.0,07:51,07:52,150.0,10:20,37200.0,148.0,0.18,0.05958,0.18,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-02-16,126.0,08:55,09:00,-10.0,08:45,31500.0,-10.0,1.11,0.36741,1.11,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-02-16,126.0,08:55,09:00,0.0,08:55,32100.0,0.0,1.01,0.33431,1.01,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-02-16,126.0,08:55,09:00,15.0,09:10,33000.0,10.0,0.95,0.31445,0.95,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-05,723.0,07:51,07:52,15.0,08:05,29100.0,13.0,0.1,0.0331,0.10,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-05,723.0,07:51,07:52,-10.0,07:40,27600.0,-11.0,0.09,0.02979,0.09,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_300339,SUB228873,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-05,723.0,07:51,07:52,0.0,07:50,28200.0,-1.0,0.11,0.03641,0.11,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_300339,SUB228873,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-05,723.0,07:51,07:52,240.0,11:50,42600.0,238.0,0.15,0.04965,0.15,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-05,723.0,07:51,07:52,180.0,10:50,39000.0,178.0,0.16,0.05296,0.16,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_300339,SUB228873,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-10-05,2010-10-05,-8.0,2010-09-18,-25.0,2010-10-13,Yes,2010-10-13,Yes,Yes,E/I/S,2010-10-13,2010-12-22,2010-11-17,2011-01-26,2012-10-05,2011-10-15,723.0,Yes,Complete,2012-10-05,723.0,,Yes,2011-01-26,105.0,,13.0,Male,,54.0,18.795520401,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-05,723.0,07:51,07:52,210.0,11:20,40800.0,208.0,0.14,0.04634,0.14,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-06-15,-27.0,09:05,09:09,210.0,12:35,45300.0,206.0,2.74,0.90694,2.74,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-06-15,-27.0,09:05,09:09,-10.0,08:50,31800.0,-15.0,1.26,0.41706,1.26,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-06-15,-27.0,09:05,09:09,180.0,12:05,43500.0,176.0,3.12,1.03272,3.12,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-06-15,-27.0,09:05,09:09,60.0,10:05,36300.0,56.0,2.81,0.93011,2.81,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-06-15,-27.0,09:05,09:09,0.0,09:05,32700.0,0.0,1.25,0.41375,1.25,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-06-15,-27.0,09:05,09:09,15.0,09:20,33600.0,11.0,1.17,0.38727,1.17,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-06-15,-27.0,09:05,09:09,30.0,09:35,34500.0,26.0,1.81,0.59911,1.81,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-02-13,216.0,08:47,08:50,-10.0,08:35,30900.0,-12.0,3.07,1.01617,3.07,NG/ML,pmol/mL,0.5 - 3.0,High,2014-01-31,,
RETAIN_350507,SUB228874,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-02-13,216.0,08:47,08:50,0.0,08:45,31500.0,-2.0,3.07,1.01617,3.07,NG/ML,pmol/mL,0.5 - 3.0,High,2014-01-31,,
RETAIN_350507,SUB228874,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-06-15,-27.0,09:05,09:09,240.0,13:05,47100.0,236.0,2.54,0.84074,2.54,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2010-11-23,134.0,08:50,08:55,-10.0,08:40,31200.0,-10.0,2.72,0.90032,2.72,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2010-11-23,134.0,08:50,08:55,0.0,08:50,31800.0,0.0,2.76,0.91356,2.76,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2010-11-23,134.0,08:50,08:55,15.0,09:05,32700.0,10.0,2.95,0.97645,2.95,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2010-11-23,134.0,08:50,08:55,30.0,09:20,33600.0,25.0,3.75,1.24125,3.75,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2010-11-23,134.0,08:50,08:55,60.0,09:50,35400.0,55.0,4.93,1.63183,4.93,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2010-11-23,134.0,08:50,08:55,90.0,10:20,37200.0,85.0,4.78,1.58218,4.78,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2010-11-23,134.0,08:50,08:55,120.0,10:50,39000.0,115.0,4.91,1.62521,4.91,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-06-15,-27.0,09:05,09:09,90.0,10:35,38100.0,86.0,2.92,0.96652,2.92,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-06-15,-27.0,09:05,09:09,120.0,11:05,39900.0,116.0,3.24,1.07244,3.24,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-06-15,-27.0,09:05,09:09,150.0,11:35,41700.0,146.0,3.3,1.0923,3.30,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-07-14,733.0,09:00,09:03,-10.0,08:48,31680.0,-12.0,0.54,0.17874,0.54,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-07-14,733.0,09:00,09:03,0.0,08:58,32280.0,-2.0,0.54,0.17874,0.54,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-07-14,733.0,09:00,09:03,15.0,09:18,33480.0,15.0,0.69,0.22839,0.69,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-07-14,733.0,09:00,09:03,30.0,09:33,34380.0,30.0,0.99,0.32769,0.99,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-07-14,733.0,09:00,09:03,60.0,10:03,36180.0,60.0,1.55,0.51305,1.55,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-07-14,733.0,09:00,09:03,90.0,10:33,37980.0,90.0,2.23,0.73813,2.23,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-07-14,733.0,09:00,09:03,120.0,11:03,39780.0,120.0,2.27,0.75137,2.27,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-07-14,733.0,09:00,09:03,150.0,11:55,42900.0,172.0,2.23,0.73813,2.23,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-07-14,733.0,09:00,09:03,180.0,12:03,43380.0,180.0,2.05,0.67855,2.05,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-07-14,733.0,09:00,09:03,210.0,12:33,45180.0,210.0,2.3,0.7613,2.30,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-07-14,733.0,09:00,09:03,240.0,13:03,46980.0,240.0,2.31,0.76461,2.31,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-07-04,357.0,09:30,09:32,120.0,11:32,41520.0,120.0,4.49,1.48619,4.49,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-07-04,357.0,09:30,09:32,150.0,12:02,43320.0,150.0,4.64,1.53584,4.64,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-07-04,357.0,09:30,09:32,180.0,12:32,45120.0,180.0,4.05,1.34055,4.05,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-07-04,357.0,09:30,09:32,210.0,13:02,46920.0,210.0,4.26,1.41006,4.26,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-07-04,357.0,09:30,09:32,240.0,13:32,48720.0,240.0,4.09,1.35379,4.09,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-02-13,216.0,08:47,08:50,15.0,09:05,32700.0,15.0,3.72,1.23132,3.72,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-02-13,216.0,08:47,08:50,30.0,09:20,33600.0,30.0,4.7,1.5557,4.70,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-07-04,357.0,09:30,09:32,-10.0,09:15,33300.0,-15.0,3.03,1.00293,3.03,NG/ML,pmol/mL,0.5 - 3.0,High,2014-01-31,,
RETAIN_350507,SUB228874,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-07-04,357.0,09:30,09:32,0.0,09:25,33900.0,-5.0,3.34,1.10554,3.34,NG/ML,pmol/mL,0.5 - 3.0,High,2014-01-31,,
RETAIN_350507,SUB228874,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-07-04,357.0,09:30,09:32,15.0,09:47,35220.0,15.0,4.51,1.49281,4.51,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-07-04,357.0,09:30,09:32,30.0,10:02,36120.0,30.0,4.06,1.34386,4.06,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-07-04,357.0,09:30,09:32,60.0,10:32,37920.0,60.0,4.26,1.41006,4.26,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-07-04,357.0,09:30,09:32,90.0,11:02,39720.0,90.0,4.13,1.36703,4.13,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-02-13,216.0,08:47,08:50,90.0,10:20,37200.0,90.0,6.0,1.986,6.00,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-02-13,216.0,08:47,08:50,120.0,10:50,39000.0,120.0,6.46,2.13826,6.46,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_350507,SUB228874,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-06-15,2010-06-15,-27.0,2010-05-28,-45.0,2010-07-12,Yes,2010-07-12,Yes,Yes,E/I/S,2010-07-12,2010-09-29,2010-08-16,2010-11-03,2012-07-14,2011-07-04,733.0,Yes,Complete,2012-07-14,733.0,,Yes,2010-11-03,114.0,,13.0,Male,163.5,51.6,19.302527846,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-02-13,216.0,08:47,08:50,60.0,09:50,35400.0,60.0,5.72,1.89332,5.72,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2010-10-24,120.0,10:03,10:04,30.0,10:33,37980.0,29.0,2.69,0.89039,2.69,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2010-10-24,120.0,10:03,10:04,0.0,10:02,36120.0,-1.0,1.41,0.46671,1.41,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2010-10-24,120.0,10:03,10:04,15.0,10:18,37080.0,14.0,2.02,0.66862,2.02,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2010-06-06,-20.0,08:30,08:32,60.0,09:30,34200.0,58.0,2.34,0.77454,2.34,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2010-10-24,120.0,10:03,10:04,60.0,11:03,39780.0,59.0,3.16,1.04596,3.16,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2010-10-24,120.0,10:03,10:04,90.0,11:33,41580.0,89.0,3.11,1.02941,3.11,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2010-10-24,120.0,10:03,10:04,120.0,12:03,43380.0,119.0,4.13,1.36703,4.13,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2010-06-06,-20.0,08:30,08:32,210.0,12:00,43200.0,208.0,2.62,0.86722,2.62,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2010-06-06,-20.0,08:30,08:32,240.0,12:30,45000.0,238.0,2.2,0.7282,2.20,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2010-10-24,120.0,10:03,10:04,-10.0,09:48,35280.0,-15.0,1.47,0.48657,1.47,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2010-06-06,-20.0,08:30,08:32,15.0,08:45,31500.0,13.0,0.66,0.21846,0.66,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2010-06-06,-20.0,08:30,08:32,30.0,09:00,32400.0,28.0,0.98,0.32438,0.98,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2010-06-06,-20.0,08:30,08:32,-10.0,08:20,30000.0,-10.0,0.52,0.17212,0.52,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2010-06-06,-20.0,08:30,08:32,0.0,08:30,30600.0,0.0,0.54,0.17874,0.54,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2010-06-06,-20.0,08:30,08:32,120.0,10:30,37800.0,118.0,3.7,1.2247,3.70,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2010-06-06,-20.0,08:30,08:32,150.0,11:00,39600.0,148.0,3.74,1.23794,3.74,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2010-06-06,-20.0,08:30,08:32,180.0,11:30,41400.0,178.0,3.03,1.00293,3.03,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_465679,SUB228875,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-06-06,2010-06-06,-20.0,2010-04-27,-60.0,2010-06-26,Yes,2010-06-26,Yes,Yes,E/I/S,2010-06-26,2010-08-28,2010-07-31,2010-10-02,2010-10-24,,120.0,No,Terminated early from protocol,2011-02-09,228.0,Failure to Return/Lost to Follow-Up,Yes,2010-10-02,98.0,,19.0,Male,170.1,67.8,23.432631702,White,White,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2010-06-06,-20.0,08:30,08:32,90.0,10:01,36060.0,89.0,2.66,0.88046,2.66,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-30,119.0,09:59,10:00,0.0,09:59,35940.0,0.0,1.03,0.34093,1.03,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-30,119.0,09:59,10:00,15.0,10:14,36840.0,14.0,1.61,0.53291,1.61,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-14,-19.0,09:30,09:31,-10.0,09:20,33600.0,-10.0,1.17,0.38727,1.17,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-25,357.0,09:31,09:32,15.0,09:46,35160.0,14.0,3.54,1.17174,3.54,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-25,357.0,09:31,09:32,30.0,10:03,36180.0,31.0,5.68,1.88008,5.68,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-30,119.0,09:59,10:00,-10.0,09:49,35340.0,-10.0,1.12,0.37072,1.12,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-25,357.0,09:31,09:32,60.0,10:31,37860.0,59.0,5.75,1.90325,5.75,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-30,119.0,09:59,10:00,30.0,10:29,37740.0,29.0,2.53,0.83743,2.53,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-30,119.0,09:59,10:00,60.0,10:59,39540.0,59.0,3.76,1.24456,3.76,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-30,119.0,09:59,10:00,90.0,11:29,41340.0,89.0,2.85,0.94335,2.85,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-30,119.0,09:59,10:00,120.0,11:59,43140.0,119.0,2.5,0.8275,2.50,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-25,357.0,09:31,09:32,210.0,13:01,46860.0,209.0,2.42,0.80102,2.42,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-25,357.0,09:31,09:32,240.0,13:31,48660.0,239.0,1.95,0.64545,1.95,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-14,-19.0,09:30,09:31,0.0,09:30,34200.0,0.0,1.17,0.38727,1.17,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-25,357.0,09:31,09:32,-10.0,09:16,33360.0,-15.0,2.0,0.662,2.00,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-25,357.0,09:31,09:32,0.0,09:30,34200.0,-1.0,1.94,0.64214,1.94,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-14,-19.0,09:30,09:31,60.0,10:30,37800.0,59.0,3.06,1.01286,3.06,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-14,-19.0,09:30,09:31,90.0,11:00,39600.0,89.0,3.28,1.08568,3.28,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-14,-19.0,09:30,09:31,120.0,11:30,41400.0,119.0,3.07,1.01617,3.07,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-14,-19.0,09:30,09:31,150.0,12:00,43200.0,149.0,2.81,0.93011,2.81,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-25,357.0,09:31,09:32,90.0,11:01,39660.0,89.0,5.57,1.84367,5.57,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-25,357.0,09:31,09:32,120.0,11:31,41460.0,119.0,4.84,1.60204,4.84,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-25,357.0,09:31,09:32,150.0,12:01,43260.0,149.0,3.73,1.23463,3.73,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-25,357.0,09:31,09:32,180.0,12:31,45060.0,179.0,2.62,0.86722,2.62,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-09-25,723.0,10:13,10:19,60.0,11:28,41280.0,69.0,5.25,1.73775,5.25,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-09-25,723.0,10:13,10:19,90.0,11:58,43080.0,99.0,5.2,1.7212,5.20,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-09-25,723.0,10:13,10:19,120.0,12:28,44880.0,129.0,5.04,1.66824,5.04,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-14,-19.0,09:30,09:31,15.0,09:45,35100.0,14.0,1.84,0.60904,1.84,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-14,-19.0,09:30,09:31,30.0,10:00,36000.0,29.0,2.93,0.96983,2.93,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-18,197.0,09:45,09:46,-10.0,09:35,34500.0,-10.0,1.34,0.44354,1.34,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-18,197.0,09:45,09:46,0.0,09:45,35100.0,0.0,1.27,0.42037,1.27,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-18,197.0,09:45,09:46,15.0,10:00,36000.0,14.0,2.56,0.84736,2.56,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-18,197.0,09:45,09:46,30.0,10:15,36900.0,29.0,3.97,1.31407,3.97,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-18,197.0,09:45,09:46,60.0,10:45,38700.0,59.0,4.5,1.4895,4.50,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-18,197.0,09:45,09:46,90.0,11:15,40500.0,89.0,3.88,1.28428,3.88,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-18,197.0,09:45,09:46,120.0,11:45,42300.0,119.0,2.87,0.94997,2.87,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-09-25,723.0,10:13,10:19,30.0,10:58,39480.0,39.0,4.81,1.59211,4.81,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-09-25,723.0,10:13,10:19,180.0,13:28,48480.0,189.0,4.1,1.3571,4.10,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-09-25,723.0,10:13,10:19,210.0,13:58,50280.0,219.0,3.56,1.17836,3.56,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-09-25,723.0,10:13,10:19,240.0,02:28,8880.0,-471.0,3.11,1.02941,3.11,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-09-25,723.0,10:13,10:19,150.0,12:58,46680.0,159.0,5.05,1.67155,5.05,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-14,-19.0,09:30,09:31,240.0,13:30,48600.0,239.0,1.53,0.50643,1.53,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-09-25,723.0,10:13,10:19,-10.0,09:50,35400.0,-23.0,2.88,0.95328,2.88,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-09-25,723.0,10:13,10:19,0.0,10:13,36780.0,0.0,2.93,0.96983,2.93,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-09-25,723.0,10:13,10:19,15.0,10:28,37680.0,9.0,3.73,1.23463,3.73,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-14,-19.0,09:30,09:31,210.0,13:00,46800.0,209.0,1.74,0.57594,1.74,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_511474,SUB228876,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-14,2010-09-14,-19.0,2010-09-04,-29.0,2010-10-03,Yes,2010-10-03,Yes,Yes,E/I/S,2010-10-03,2010-12-05,2010-11-07,2011-01-09,2012-09-25,2011-09-25,723.0,Yes,Complete,2012-09-25,723.0,,Yes,2011-01-09,98.0,,33.0,Male,180.0,94.2,29.074074074,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-14,-19.0,09:30,09:31,180.0,12:30,45000.0,179.0,2.27,0.75137,2.27,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2011-10-30,126.0,09:23,09:25,0.0,09:23,33780.0,0.0,1.32,0.43692,1.32,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2011-10-30,126.0,09:23,09:25,15.0,09:40,34800.0,15.0,1.73,0.57263,1.73,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2011-10-30,126.0,09:23,09:25,-10.0,09:10,33000.0,-13.0,1.46,0.48326,1.46,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2015,000,PIV15,Visit 15/Week 19,2012-01-17,205.0,09:36,09:38,0.0,09:35,34500.0,-1.0,0.38,0.12578,0.38,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_516891,SUB228877,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-07-25,395.0,08:45,08:45,150.0,11:15,40500.0,150.0,0.29,0.09599,0.29,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2011-10-30,126.0,09:23,09:25,90.0,10:55,39300.0,90.0,1.86,0.61566,1.86,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2011-10-30,126.0,09:23,09:25,120.0,11:25,41100.0,120.0,2.01,0.66531,2.01,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2015,000,PIV15,Visit 15/Week 19,2012-01-17,205.0,09:36,09:38,60.0,10:35,38100.0,57.0,1.57,0.51967,1.57,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2011-10-30,126.0,09:23,09:25,30.0,09:55,35700.0,30.0,2.33,0.77123,2.33,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2015,000,PIV15,Visit 15/Week 19,2012-01-17,205.0,09:36,09:38,15.0,09:50,35400.0,12.0,0.48,0.15888,0.48,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2015,000,PIV15,Visit 15/Week 19,2012-01-17,205.0,09:36,09:38,30.0,10:05,36300.0,27.0,0.88,0.29128,0.88,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-05-29,-28.0,09:15,09:20,180.0,12:15,44100.0,175.0,3.3,1.0923,3.30,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-05-29,-28.0,09:15,09:20,210.0,12:45,45900.0,205.0,2.81,0.93011,2.81,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2011-10-30,126.0,09:23,09:25,60.0,10:27,37620.0,62.0,1.84,0.60904,1.84,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-05-29,-28.0,09:15,09:20,150.0,11:45,42300.0,145.0,3.19,1.05589,3.19,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2015,000,PIV15,Visit 15/Week 19,2012-01-17,205.0,09:36,09:38,-10.0,09:25,33900.0,-11.0,0.38,0.12578,0.38,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_516891,SUB228877,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-05-29,-28.0,09:15,09:20,-10.0,09:05,32700.0,-10.0,1.11,0.36741,1.11,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-05-29,-28.0,09:15,09:20,0.0,09:15,33300.0,0.0,1.07,0.35417,1.07,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-05-29,-28.0,09:15,09:20,15.0,09:30,34200.0,10.0,1.57,0.51967,1.57,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-05-29,-28.0,09:15,09:20,30.0,09:45,35100.0,25.0,2.15,0.71165,2.15,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-05-29,-28.0,09:15,09:20,60.0,10:15,36900.0,55.0,3.14,1.03934,3.14,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-05-29,-28.0,09:15,09:20,90.0,10:45,38700.0,85.0,2.88,0.95328,2.88,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-05-29,-28.0,09:15,09:20,120.0,11:15,40500.0,115.0,3.08,1.01948,3.08,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2015,000,PIV15,Visit 15/Week 19,2012-01-17,205.0,09:36,09:38,90.0,11:05,39900.0,87.0,1.7,0.5627,1.70,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2015,000,PIV15,Visit 15/Week 19,2012-01-17,205.0,09:36,09:38,120.0,11:35,41700.0,117.0,1.76,0.58256,1.76,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-07-25,395.0,08:45,08:45,90.0,10:15,36900.0,90.0,0.25,0.08275,0.25,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-05-29,-28.0,09:15,09:20,240.0,13:15,47700.0,235.0,2.53,0.83743,2.53,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-07-25,395.0,08:45,08:45,30.0,09:15,33300.0,30.0,0.22,0.07282,0.22,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-07-25,395.0,08:45,08:45,60.0,09:45,35100.0,60.0,0.28,0.09268,0.28,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-07-25,395.0,08:45,08:45,180.0,11:45,42300.0,180.0,0.26,0.08606,0.26,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-07-25,395.0,08:45,08:45,120.0,10:45,38700.0,120.0,0.31,0.10261,0.31,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-07-25,395.0,08:45,08:45,240.0,12:45,45900.0,240.0,0.23,0.07613,0.23,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-07-25,395.0,08:45,08:45,0.0,08:45,31500.0,0.0,0.12,0.03972,0.12,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_516891,SUB228877,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-07-25,395.0,08:45,08:45,15.0,09:00,32400.0,15.0,0.15,0.04965,0.15,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-07-25,395.0,08:45,08:45,210.0,12:15,44100.0,210.0,0.25,0.08275,0.25,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_516891,SUB228877,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-05-29,2011-05-29,-28.0,2011-04-30,-57.0,2011-06-26,Yes,2011-06-26,Yes,Yes,E/I/S,2011-06-26,2011-09-04,2011-07-31,2011-10-09,2012-11-06,2012-07-25,499.0,No,Terminated early from protocol,2013-02-05,590.0,Failure to Return/Lost to Follow-Up,Yes,2011-10-09,105.0,,12.0,Male,154.9,43.9,18.296233102,White,Multiple Races,Not Hispanic or Latino,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-07-25,395.0,08:45,08:45,-10.0,08:35,30900.0,-10.0,0.12,0.03972,0.12,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_615116,SUB228878,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-11-29,-19.0,09:45,09:46,60.0,10:46,38760.0,60.0,1.92,0.63552,1.92,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-12-10,723.0,09:18,09:23,30.0,09:53,35580.0,30.0,2.22,0.73482,2.22,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-11-29,-19.0,09:45,09:46,240.0,13:46,49560.0,240.0,1.53,0.50643,1.53,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-11-29,-19.0,09:45,09:46,30.0,10:16,36960.0,30.0,1.78,0.58918,1.78,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-12-10,723.0,09:18,09:23,-10.0,09:05,32700.0,-13.0,1.16,0.38396,1.16,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-12-10,723.0,09:18,09:23,0.0,09:16,33360.0,-2.0,1.17,0.38727,1.17,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-25,219.0,08:44,08:47,60.0,09:47,35220.0,60.0,1.63,0.53953,1.63,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-25,219.0,08:44,08:47,90.0,10:17,37020.0,90.0,1.93,0.63883,1.93,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-25,219.0,08:44,08:47,120.0,10:47,38820.0,120.0,2.15,0.71165,2.15,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-13,360.0,09:05,09:10,60.0,10:10,36600.0,60.0,1.71,0.56601,1.71,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-13,360.0,09:05,09:10,90.0,10:40,38400.0,90.0,1.72,0.56932,1.72,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-13,360.0,09:05,09:10,120.0,11:10,40200.0,120.0,1.73,0.57263,1.73,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-13,360.0,09:05,09:10,150.0,11:40,42000.0,150.0,1.84,0.60904,1.84,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-13,360.0,09:05,09:10,180.0,12:10,43800.0,180.0,1.75,0.57925,1.75,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-13,360.0,09:05,09:10,210.0,12:40,45600.0,210.0,1.77,0.58587,1.77,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-13,360.0,09:05,09:10,240.0,13:10,47400.0,240.0,1.5,0.4965,1.50,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-25,219.0,08:44,08:47,0.0,08:40,31200.0,-4.0,0.77,0.25487,0.77,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-25,219.0,08:44,08:47,15.0,09:02,32520.0,15.0,0.91,0.30121,0.91,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-25,219.0,08:44,08:47,30.0,09:17,33420.0,30.0,1.27,0.42037,1.27,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-13,360.0,09:05,09:10,0.0,09:05,32700.0,0.0,1.0,0.331,1.00,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-13,360.0,09:05,09:10,15.0,09:25,33900.0,15.0,1.2,0.3972,1.20,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-13,360.0,09:05,09:10,30.0,09:40,34800.0,30.0,1.4,0.4634,1.40,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-07,140.0,08:48,08:49,60.0,09:49,35340.0,60.0,1.21,0.40051,1.21,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-07,140.0,08:48,08:49,90.0,10:19,37140.0,90.0,1.23,0.40713,1.23,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-07,140.0,08:48,08:49,120.0,10:49,38940.0,120.0,1.32,0.43692,1.32,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-11-29,-19.0,09:45,09:46,90.0,11:16,40560.0,90.0,2.33,0.77123,2.33,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-11-29,-19.0,09:45,09:46,120.0,11:46,42360.0,120.0,2.3,0.7613,2.30,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-11-29,-19.0,09:45,09:46,150.0,12:16,44160.0,150.0,2.01,0.66531,2.01,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-11-29,-19.0,09:45,09:46,180.0,12:46,45960.0,180.0,1.85,0.61235,1.85,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-11-29,-19.0,09:45,09:46,210.0,13:16,47760.0,210.0,1.78,0.58918,1.78,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2015,000,PIV15,Visit 15/Week 19,2011-07-25,219.0,08:44,08:47,-10.0,08:30,30600.0,-14.0,0.79,0.26149,0.79,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-12-13,360.0,09:05,09:10,-10.0,08:55,32100.0,-10.0,0.95,0.31445,0.95,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-11-29,-19.0,09:45,09:46,-10.0,09:35,34500.0,-10.0,0.86,0.28466,0.86,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-11-29,-19.0,09:45,09:46,0.0,09:45,35100.0,0.0,0.85,0.28135,0.85,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-11-29,-19.0,09:45,09:46,15.0,10:01,36060.0,15.0,1.16,0.38396,1.16,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-12-10,723.0,09:18,09:23,150.0,11:53,42780.0,150.0,3.2,1.0592,3.20,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-12-10,723.0,09:18,09:23,180.0,12:23,44580.0,180.0,3.15,1.04265,3.15,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-12-10,723.0,09:18,09:23,210.0,12:53,46380.0,210.0,3.19,1.05589,3.19,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-12-10,723.0,09:18,09:23,240.0,13:23,48180.0,240.0,2.64,0.87384,2.64,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-12-10,723.0,09:18,09:23,120.0,11:23,40980.0,120.0,3.22,1.06582,3.22,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-07,140.0,08:48,08:49,30.0,09:19,33540.0,30.0,1.1,0.3641,1.10,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-12-10,723.0,09:18,09:23,60.0,10:23,37380.0,60.0,3.12,1.03272,3.12,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-12-10,723.0,09:18,09:23,90.0,10:53,39180.0,90.0,3.54,1.17174,3.54,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-07,140.0,08:48,08:49,0.0,08:48,31680.0,0.0,0.66,0.21846,0.66,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-07,140.0,08:48,08:49,15.0,09:04,32640.0,15.0,1.13,0.37403,1.13,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_615116,SUB228878,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2010-11-29,2010-11-29,-19.0,2010-09-10,-99.0,2010-12-18,Yes,2010-12-18,Yes,Yes,E/I/S,2010-12-18,2011-03-12,2011-01-22,2011-04-16,,2011-12-13,,,Active,,,,Yes,,,,13.0,Male,155.3,40.8,16.91676248,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2014,000,PIV14,Visit 14/Week 8,2011-05-07,140.0,08:48,08:49,-10.0,08:38,31080.0,-10.0,0.62,0.20522,0.62,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-03-25,363.0,09:20,09:21,180.0,12:21,44460.0,180.0,0.69,0.22839,0.69,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-03-25,363.0,09:20,09:21,120.0,11:21,40860.0,120.0,0.85,0.28135,0.85,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-03-25,363.0,09:20,09:21,150.0,11:51,42660.0,150.0,0.77,0.25487,0.77,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-03-25,363.0,09:20,09:21,30.0,09:51,35460.0,30.0,0.4,0.1324,0.40,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-03-25,363.0,09:20,09:21,210.0,12:51,46260.0,210.0,0.61,0.20191,0.61,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-03-25,363.0,09:20,09:21,240.0,13:21,48060.0,240.0,0.6,0.1986,0.60,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-03-18,-9.0,09:45,09:49,-10.0,09:35,34500.0,-10.0,0.97,0.32107,0.97,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-03-18,-9.0,09:45,09:49,240.0,13:49,49740.0,240.0,1.33,0.44023,1.33,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-03-25,363.0,09:20,09:21,60.0,10:21,37260.0,60.0,0.5,0.1655,0.50,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-03-25,363.0,09:20,09:21,90.0,10:51,39060.0,90.0,0.68,0.22508,0.68,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-03-18,-9.0,09:45,09:49,210.0,13:19,47940.0,210.0,1.52,0.50312,1.52,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-03-31,735.0,09:43,09:45,90.0,11:15,40500.0,90.0,0.31,0.10261,0.31,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2015,000,PIV15,Visit 15/Week 19,2010-10-10,197.0,08:50,08:52,90.0,10:22,37320.0,90.0,0.99,0.32769,0.99,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2015,000,PIV15,Visit 15/Week 19,2010-10-10,197.0,08:50,08:52,120.0,10:52,39120.0,120.0,0.99,0.32769,0.99,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-03-31,735.0,09:43,09:45,60.0,10:45,38700.0,60.0,0.25,0.08275,0.25,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-03-25,363.0,09:20,09:21,15.0,09:36,34560.0,15.0,0.33,0.10923,0.33,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-03-18,-9.0,09:45,09:49,120.0,11:49,42540.0,120.0,2.06,0.68186,2.06,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-03-18,-9.0,09:45,09:49,150.0,12:19,44340.0,150.0,2.12,0.70172,2.12,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-03-18,-9.0,09:45,09:49,180.0,12:49,46140.0,180.0,1.87,0.61897,1.87,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-03-31,735.0,09:43,09:45,-10.0,09:35,34500.0,-8.0,0.15,0.04965,0.15,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_703798,SUB228879,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-03-31,735.0,09:43,09:45,0.0,09:43,34980.0,0.0,0.17,0.05627,0.17,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_703798,SUB228879,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-03-31,735.0,09:43,09:45,15.0,10:00,36000.0,15.0,0.23,0.07613,0.23,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-03-31,735.0,09:43,09:45,30.0,10:15,36900.0,30.0,0.21,0.06951,0.21,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2014,000,PIV14,Visit 14/Week 8,2010-07-24,119.0,09:54,09:59,60.0,10:59,39540.0,60.0,1.66,0.54946,1.66,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2014,000,PIV14,Visit 14/Week 8,2010-07-24,119.0,09:54,09:59,90.0,11:29,41340.0,90.0,1.71,0.56601,1.71,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-03-18,-9.0,09:45,09:49,0.0,09:45,35100.0,0.0,0.88,0.29128,0.88,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-03-18,-9.0,09:45,09:49,15.0,10:04,36240.0,15.0,1.06,0.35086,1.06,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-03-25,363.0,09:20,09:21,-10.0,09:15,33300.0,-5.0,0.2,0.0662,0.20,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_703798,SUB228879,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2017,000,PIV17,Visit 17/Week 52,2011-03-25,363.0,09:20,09:21,0.0,09:20,33600.0,0.0,0.2,0.0662,0.20,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_703798,SUB228879,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-03-31,735.0,09:43,09:45,240.0,13:45,49500.0,240.0,0.42,0.13902,0.42,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-03-18,-9.0,09:45,09:49,90.0,11:19,40740.0,90.0,1.89,0.62559,1.89,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2015,000,PIV15,Visit 15/Week 19,2010-10-10,197.0,08:50,08:52,-10.0,08:40,31200.0,-10.0,0.61,0.20191,0.61,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2015,000,PIV15,Visit 15/Week 19,2010-10-10,197.0,08:50,08:52,0.0,08:50,31800.0,0.0,0.58,0.19198,0.58,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2015,000,PIV15,Visit 15/Week 19,2010-10-10,197.0,08:50,08:52,15.0,09:07,32820.0,15.0,0.75,0.24825,0.75,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2015,000,PIV15,Visit 15/Week 19,2010-10-10,197.0,08:50,08:52,30.0,09:22,33720.0,30.0,0.8,0.2648,0.80,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2015,000,PIV15,Visit 15/Week 19,2010-10-10,197.0,08:50,08:52,60.0,09:52,35520.0,60.0,0.92,0.30452,0.92,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-03-31,735.0,09:43,09:45,150.0,12:15,44100.0,150.0,0.42,0.13902,0.42,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-03-18,-9.0,09:45,09:49,30.0,10:19,37140.0,30.0,1.41,0.46671,1.41,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2014,000,PIV14,Visit 14/Week 8,2010-07-24,119.0,09:54,09:59,120.0,11:59,43140.0,120.0,2.13,0.70503,2.13,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-03-31,735.0,09:43,09:45,120.0,11:45,42300.0,120.0,0.44,0.14564,0.44,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2014,000,PIV14,Visit 14/Week 8,2010-07-24,119.0,09:54,09:59,30.0,10:29,37740.0,30.0,1.31,0.43361,1.31,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2014,000,PIV14,Visit 14/Week 8,2010-07-24,119.0,09:54,09:59,-10.0,09:43,34980.0,-11.0,0.79,0.26149,0.79,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,1000,000,PIV-1,Visit -1/Week -1,2010-03-18,-9.0,09:45,09:49,60.0,10:49,38940.0,60.0,1.64,0.54284,1.64,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2014,000,PIV14,Visit 14/Week 8,2010-07-24,119.0,09:54,09:59,15.0,10:14,36840.0,15.0,1.14,0.37734,1.14,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2014,000,PIV14,Visit 14/Week 8,2010-07-24,119.0,09:54,09:59,0.0,09:53,35580.0,-1.0,0.78,0.25818,0.78,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-03-31,735.0,09:43,09:45,210.0,13:15,47700.0,210.0,0.45,0.14895,0.45,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_703798,SUB228879,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-03-14,2010-03-18,-9.0,2009-12-18,-99.0,2010-03-27,Yes,2010-03-27,Yes,Yes,E/I/S,2010-03-27,2010-05-29,2010-05-01,2010-07-03,,2011-03-25,,,Active,,,,Yes,,,,17.0,Female,165.1,51.8,19.003588303,White,Multiple Races,Not Hispanic or Latino,Completed therapy,2021,000,PIV21,Visit 21/Week 104,2012-03-31,735.0,09:43,09:45,180.0,12:45,45900.0,180.0,0.51,0.16881,0.51,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-08-15,-35.0,09:57,09:59,15.0,10:12,36720.0,13.0,2.32,0.76792,2.32,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-08-15,-35.0,09:57,09:59,30.0,10:27,37620.0,28.0,2.83,0.93673,2.83,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-22,368.0,09:30,09:31,0.0,09:30,34200.0,0.0,1.82,0.60242,1.82,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-22,368.0,09:30,09:31,120.0,11:30,41400.0,119.0,2.97,0.98307,2.97,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-22,368.0,09:30,09:31,-10.0,09:20,33600.0,-10.0,1.75,0.57925,1.75,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-22,368.0,09:30,09:31,210.0,13:00,46800.0,209.0,2.88,0.95328,2.88,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-22,368.0,09:30,09:31,240.0,13:30,48600.0,239.0,2.81,0.93011,2.81,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-22,368.0,09:30,09:31,150.0,12:00,43200.0,149.0,3.18,1.05258,3.18,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-22,368.0,09:30,09:31,180.0,12:30,45000.0,179.0,2.9,0.9599,2.90,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-08-15,-35.0,09:57,09:59,180.0,12:57,46620.0,178.0,5.25,1.73775,5.25,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-08-15,-35.0,09:57,09:59,210.0,13:27,48420.0,208.0,4.5,1.4895,4.50,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-22,368.0,09:30,09:31,15.0,09:45,35100.0,14.0,1.66,0.54946,1.66,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-22,368.0,09:30,09:31,30.0,10:00,36000.0,29.0,2.39,0.79109,2.39,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-22,368.0,09:30,09:31,60.0,10:30,37800.0,59.0,2.71,0.89701,2.71,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-09-22,368.0,09:30,09:31,90.0,11:00,39600.0,89.0,2.89,0.95659,2.89,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-08-15,-35.0,09:57,09:59,-10.0,09:47,35220.0,-10.0,2.29,0.75799,2.29,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-08-15,-35.0,09:57,09:59,0.0,09:57,35820.0,0.0,2.45,0.81095,2.45,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-16,119.0,09:45,09:47,-10.0,09:35,34500.0,-10.0,1.48,0.48988,1.48,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-08-15,-35.0,09:57,09:59,60.0,10:57,39420.0,58.0,4.69,1.55239,4.69,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-08-15,-35.0,09:57,09:59,90.0,11:27,41220.0,88.0,5.02,1.66162,5.02,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-08-15,-35.0,09:57,09:59,120.0,11:57,43020.0,118.0,5.89,1.94959,5.89,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-08-15,-35.0,09:57,09:59,150.0,12:27,44820.0,148.0,5.35,1.77085,5.35,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-06,748.0,09:06,09:09,-10.0,08:55,32100.0,-11.0,0.58,0.19198,0.58,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-16,119.0,09:45,09:47,90.0,11:15,40500.0,88.0,3.02,0.99962,3.02,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-06,748.0,09:06,09:09,0.0,09:05,32700.0,-1.0,0.55,0.18205,0.55,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-06,748.0,09:06,09:09,15.0,09:20,33600.0,11.0,0.56,0.18536,0.56,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-06,748.0,09:06,09:09,30.0,09:35,34500.0,26.0,0.68,0.22508,0.68,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-06,748.0,09:06,09:09,60.0,10:05,36300.0,56.0,0.65,0.21515,0.65,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-06,748.0,09:06,09:09,90.0,10:35,38100.0,86.0,0.68,0.22508,0.68,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-06,748.0,09:06,09:09,120.0,11:05,39900.0,116.0,0.73,0.24163,0.73,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-06,748.0,09:06,09:09,150.0,11:35,41700.0,146.0,0.9,0.2979,0.90,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-06,748.0,09:06,09:09,180.0,12:05,43500.0,176.0,0.82,0.27142,0.82,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-06,748.0,09:06,09:09,210.0,12:35,45300.0,206.0,0.87,0.28797,0.87,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-06,748.0,09:06,09:09,240.0,13:05,47100.0,236.0,0.96,0.31776,0.96,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-16,119.0,09:45,09:47,30.0,10:15,36900.0,28.0,1.46,0.48326,1.46,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-16,119.0,09:45,09:47,60.0,10:45,38700.0,58.0,1.95,0.64545,1.95,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-08,201.0,08:15,08:15,60.0,09:15,33300.0,60.0,2.83,0.93673,2.83,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-16,119.0,09:45,09:47,120.0,11:45,42300.0,118.0,4.75,1.57225,4.75,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-08-15,-35.0,09:57,09:59,240.0,13:57,50220.0,238.0,4.06,1.34386,4.06,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-08,201.0,08:15,08:15,15.0,08:30,30600.0,15.0,1.69,0.55939,1.69,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-08,201.0,08:15,08:15,-10.0,08:05,29100.0,-10.0,1.83,0.60573,1.83,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-16,119.0,09:45,09:47,0.0,09:45,35100.0,0.0,1.49,0.49319,1.49,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-16,119.0,09:45,09:47,15.0,10:00,36000.0,13.0,1.37,0.45347,1.37,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-08,201.0,08:15,08:15,120.0,10:15,36900.0,120.0,3.59,1.18829,3.59,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-08,201.0,08:15,08:15,30.0,08:45,31500.0,30.0,2.69,0.89039,2.69,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-08,201.0,08:15,08:15,90.0,09:45,35100.0,90.0,3.29,1.08899,3.29,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_731341,SUB228880,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-08-15,2010-08-15,-35.0,2010-06-09,-102.0,2010-09-19,Yes,2010-09-19,Yes,Yes,E/I/S,2010-09-19,2010-11-21,2010-10-24,2010-12-26,2012-10-06,2011-09-22,748.0,Yes,Complete,2012-10-06,748.0,,Yes,2010-12-26,98.0,,18.0,Male,174.2,69.3,22.836888594,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-08,201.0,08:15,08:15,0.0,08:15,29700.0,0.0,1.83,0.60573,1.83,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-29,119.0,07:58,07:58,60.0,08:45,31500.0,47.0,1.18,0.39058,1.18,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-29,119.0,07:58,07:58,30.0,08:15,29700.0,17.0,0.61,0.20191,0.61,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-03,366.0,08:41,08:42,240.0,12:40,45600.0,238.0,0.3,0.0993,0.30,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-29,119.0,07:58,07:58,90.0,09:15,33300.0,77.0,1.46,0.48326,1.46,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-29,119.0,07:58,07:58,15.0,08:00,28800.0,2.0,0.58,0.19198,0.58,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-04,-28.0,09:40,09:40,-10.0,09:30,34200.0,-10.0,0.12,0.03972,0.12,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_775379,SUB228881,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-04,-28.0,09:40,09:40,0.0,09:40,34800.0,0.0,0.16,0.05296,0.16,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_775379,SUB228881,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-04,-28.0,09:40,09:40,15.0,09:55,35700.0,15.0,0.15,0.04965,0.15,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-29,119.0,07:58,07:58,120.0,09:45,35100.0,107.0,1.7,0.5627,1.70,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-04,-28.0,09:40,09:40,60.0,10:40,38400.0,60.0,0.32,0.10592,0.32,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-04,-28.0,09:40,09:40,90.0,11:10,40200.0,90.0,0.35,0.11585,0.35,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-04,-28.0,09:40,09:40,120.0,11:40,42000.0,120.0,0.4,0.1324,0.40,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-04,-28.0,09:40,09:40,30.0,10:10,36600.0,30.0,0.21,0.06951,0.21,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-02,731.0,08:48,08:49,-10.0,08:35,30900.0,-13.0,0.13,0.04303,0.13,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_775379,SUB228881,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-02,731.0,08:48,08:49,0.0,08:45,31500.0,-3.0,0.12,0.03972,0.12,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_775379,SUB228881,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-02,731.0,08:48,08:49,15.0,09:03,32580.0,14.0,0.15,0.04965,0.15,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-29,119.0,07:58,07:58,-10.0,07:45,27900.0,-13.0,0.48,0.15888,0.48,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_775379,SUB228881,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-01-29,119.0,07:58,07:58,0.0,07:55,28500.0,-3.0,0.52,0.17212,0.52,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-02,731.0,08:48,08:49,30.0,09:18,33480.0,29.0,0.21,0.06951,0.21,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-02,731.0,08:48,08:49,60.0,09:48,35280.0,59.0,0.42,0.13902,0.42,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-02,731.0,08:48,08:49,90.0,10:18,37080.0,89.0,0.49,0.16219,0.49,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-02,731.0,08:48,08:49,120.0,10:48,38880.0,119.0,0.49,0.16219,0.49,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-02,731.0,08:48,08:49,150.0,11:18,40680.0,149.0,0.55,0.18205,0.55,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-02,731.0,08:48,08:49,180.0,11:48,42480.0,179.0,0.41,0.13571,0.41,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-02,731.0,08:48,08:49,210.0,12:18,44280.0,209.0,0.42,0.13902,0.42,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-04,-28.0,09:40,09:40,150.0,12:10,43800.0,150.0,0.4,0.1324,0.40,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-04,-28.0,09:40,09:40,180.0,12:40,45600.0,180.0,0.46,0.15226,0.46,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-04,-28.0,09:40,09:40,210.0,13:10,47400.0,210.0,0.47,0.15557,0.47,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2010-09-04,-28.0,09:40,09:40,240.0,13:40,49200.0,240.0,0.41,0.13571,0.41,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-03,366.0,08:41,08:42,210.0,12:10,43800.0,208.0,0.34,0.11254,0.34,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-13,193.0,07:51,07:51,30.0,08:20,30000.0,29.0,0.59,0.19529,0.59,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-13,193.0,07:51,07:51,-10.0,07:40,27600.0,-11.0,0.25,0.08275,0.25,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_775379,SUB228881,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-13,193.0,07:51,07:51,0.0,07:50,28200.0,-1.0,0.22,0.07282,0.22,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_775379,SUB228881,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-13,193.0,07:51,07:51,15.0,08:05,29100.0,14.0,0.47,0.15557,0.47,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-03,366.0,08:41,08:42,60.0,09:40,34800.0,58.0,0.36,0.11916,0.36,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-13,193.0,07:51,07:51,60.0,08:50,31800.0,59.0,1.23,0.40713,1.23,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-13,193.0,07:51,07:51,90.0,09:20,33600.0,89.0,1.45,0.47995,1.45,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-04-13,193.0,07:51,07:51,120.0,09:50,35400.0,119.0,1.48,0.48988,1.48,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-03,366.0,08:41,08:42,180.0,11:40,42000.0,178.0,0.45,0.14895,0.45,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-03,366.0,08:41,08:42,90.0,10:10,36600.0,88.0,0.48,0.15888,0.48,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-03,366.0,08:41,08:42,120.0,10:40,38400.0,118.0,0.53,0.17543,0.53,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-03,366.0,08:41,08:42,150.0,11:10,40200.0,148.0,0.5,0.1655,0.50,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-03,366.0,08:41,08:42,15.0,08:55,32100.0,13.0,0.09,0.02979,0.09,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-03,366.0,08:41,08:42,30.0,09:10,33000.0,28.0,0.19,0.06289,0.19,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_775379,SUB228881,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-03,366.0,08:41,08:42,-10.0,08:32,30720.0,-9.0,0.09,0.02979,0.09,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_775379,SUB228881,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2011-10-03,366.0,08:41,08:42,0.0,08:40,31200.0,-1.0,0.09,0.02979,0.09,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_775379,SUB228881,Visit 21 (Week 104),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2010-09-04,2010-09-04,-28.0,2010-08-10,-53.0,2010-10-02,Yes,2010-10-02,Yes,Yes,E/I/S,2010-10-02,2010-12-04,2010-11-06,2011-01-08,2012-10-02,2011-10-03,731.0,Yes,Complete,2012-10-02,731.0,,Yes,2011-01-08,98.0,,23.0,Male,175.5,84.3,27.369907712,White,White,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2012-10-02,731.0,08:48,08:49,240.0,12:48,46080.0,239.0,0.43,0.14233,0.43,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-12,-16.0,09:10,09:11,0.0,09:10,33000.0,0.0,2.03,0.67193,2.03,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-08-22,147.0,09:20,09:21,120.0,11:20,40800.0,119.0,3.59,1.18829,3.59,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-12,-16.0,09:10,09:11,30.0,09:40,34800.0,29.0,2.95,0.97645,2.95,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-12,-16.0,09:10,09:11,60.0,10:10,36600.0,59.0,3.37,1.11547,3.37,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-12,-16.0,09:10,09:11,90.0,10:40,38400.0,89.0,3.07,1.01617,3.07,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-12,-16.0,09:10,09:11,15.0,09:25,33900.0,14.0,1.96,0.64876,1.96,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-08-22,147.0,09:20,09:21,30.0,09:50,35400.0,29.0,2.67,0.88377,2.67,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-08-22,147.0,09:20,09:21,60.0,10:20,37200.0,59.0,3.16,1.04596,3.16,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-08-22,147.0,09:20,09:21,90.0,10:50,39000.0,89.0,3.08,1.01948,3.08,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-12,-16.0,09:10,09:11,-10.0,09:00,32400.0,-10.0,1.86,0.61566,1.86,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-11-07,224.0,09:45,09:46,120.0,11:45,42300.0,119.0,3.06,1.01286,3.06,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-03-19,357.0,11:25,11:26,180.0,14:25,51900.0,179.0,4.06,1.34386,4.06,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-03-19,357.0,11:25,11:26,210.0,14:55,53700.0,209.0,3.29,1.08899,3.29,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-03-19,357.0,11:25,11:26,240.0,15:25,55500.0,239.0,2.58,0.85398,2.58,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-12,-16.0,09:10,09:11,120.0,11:10,40200.0,119.0,3.68,1.21808,3.68,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-12,-16.0,09:10,09:11,150.0,11:40,42000.0,149.0,3.09,1.02279,3.09,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-12,-16.0,09:10,09:11,180.0,12:10,43800.0,179.0,3.0,0.993,3.00,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-12,-16.0,09:10,09:11,210.0,12:40,45600.0,209.0,2.49,0.82419,2.49,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit -1 (Week -1),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,1000,000,PIV-1,Visit -1/Week -1,2011-03-12,-16.0,09:10,09:11,240.0,13:10,47400.0,239.0,2.57,0.85067,2.57,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-08-22,147.0,09:20,09:21,15.0,09:35,34500.0,14.0,1.8,0.5958,1.80,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-03-19,357.0,11:25,11:26,60.0,12:25,44700.0,59.0,3.0,0.993,3.00,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-03-19,357.0,11:25,11:26,90.0,12:55,46500.0,89.0,3.69,1.22139,3.69,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-03-19,357.0,11:25,11:26,120.0,13:25,48300.0,119.0,3.65,1.20815,3.65,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-03-19,357.0,11:25,11:26,150.0,13:55,50100.0,149.0,4.04,1.33724,4.04,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-04-03,737.0,09:25,09:26,30.0,09:55,35700.0,29.0,0.64,0.21184,0.64,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-04-03,737.0,09:25,09:26,60.0,10:25,37500.0,59.0,0.77,0.25487,0.77,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-04-03,737.0,09:25,09:26,90.0,10:55,39300.0,89.0,0.83,0.27473,0.83,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-04-03,737.0,09:25,09:26,120.0,11:25,41100.0,119.0,0.87,0.28797,0.87,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-03-19,357.0,11:25,11:26,-10.0,11:15,40500.0,-10.0,1.36,0.45016,1.36,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-03-19,357.0,11:25,11:26,0.0,11:25,41100.0,0.0,1.41,0.46671,1.41,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-08-22,147.0,09:20,09:21,-10.0,09:10,33000.0,-10.0,1.52,0.50312,1.52,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 14 (Week 8),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2014,000,PIV14,Visit 14/Week 8,2011-08-22,147.0,09:20,09:21,0.0,09:20,33600.0,0.0,1.47,0.48657,1.47,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-03-19,357.0,11:25,11:26,30.0,11:55,42900.0,29.0,2.27,0.75137,2.27,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-11-07,224.0,09:45,09:46,15.0,10:00,36000.0,14.0,1.55,0.51305,1.55,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-11-07,224.0,09:45,09:46,30.0,10:15,36900.0,29.0,2.18,0.72158,2.18,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-11-07,224.0,09:45,09:46,60.0,10:45,38700.0,59.0,3.12,1.03272,3.12,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-11-07,224.0,09:45,09:46,90.0,11:15,40500.0,89.0,3.52,1.16512,3.52,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-04-03,737.0,09:25,09:26,150.0,11:55,42900.0,149.0,0.83,0.27473,0.83,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-04-03,737.0,09:25,09:26,180.0,12:25,44700.0,179.0,0.77,0.25487,0.77,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 17 (Week 52),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2017,000,PIV17,Visit 17/Week 52,2012-03-19,357.0,11:25,11:26,15.0,11:40,42000.0,14.0,2.33,0.77123,2.33,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-11-07,224.0,09:45,09:46,-10.0,09:35,34500.0,-10.0,1.13,0.37403,1.13,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 15 (Week 19),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2015,000,PIV15,Visit 15/Week 19,2011-11-07,224.0,09:45,09:46,0.0,09:45,35100.0,0.0,1.13,0.37403,1.13,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-04-02,736.0,09:25,09:26,15.0,09:40,34800.0,14.0,1.61,0.53291,1.61,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-04-03,737.0,09:25,09:26,-10.0,09:15,33300.0,-10.0,0.45,0.14895,0.45,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_820343,SUB228882,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-04-03,737.0,09:25,09:26,0.0,09:25,33900.0,0.0,0.43,0.14233,0.43,NG/ML,pmol/mL,0.5 - 3.0,Low,2014-01-31,,
RETAIN_820343,SUB228882,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-04-03,737.0,09:25,09:26,15.0,09:40,34800.0,14.0,0.54,0.17874,0.54,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-04-03,737.0,09:25,09:26,210.0,12:55,46500.0,209.0,0.74,0.24494,0.74,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_820343,SUB228882,Visit 21 (Week 104),ITN041AI,Part 1a,Pediatric,Alpha-1 Antitrypsin,2011-03-12,2011-03-12,-16.0,2011-03-08,-20.0,2011-03-28,Yes,2011-03-28,Yes,Yes,E/I/S,2011-03-28,2011-06-27,2011-05-02,2011-08-01,2013-04-02,2012-03-19,736.0,Yes,Complete,2013-04-02,736.0,,Yes,2011-08-01,126.0,,8.0,Female,144.5,55.5,26.580141521,White,Multiple Races,Not Hispanic or Latino,Completed study and therapy,2021,000,PIV21,Visit 21/Week 104,2013-04-03,737.0,09:25,09:26,240.0,13:25,48300.0,239.0,0.62,0.20522,0.62,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2015,000,PIV15,Visit 15/Week 19,2011-09-27,196.0,08:50,08:51,0.0,08:50,31800.0,0.0,0.71,0.23501,0.71,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2015,000,PIV15,Visit 15/Week 19,2011-09-27,196.0,08:50,08:51,15.0,09:05,32700.0,14.0,0.81,0.26811,0.81,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-14.0,09:50,09:52,60.0,10:50,39000.0,58.0,1.77,0.58587,1.77,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-14.0,09:50,09:52,90.0,11:20,40800.0,88.0,1.96,0.64876,1.96,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2015,000,PIV15,Visit 15/Week 19,2011-09-27,196.0,08:50,08:51,30.0,09:20,33600.0,29.0,1.16,0.38396,1.16,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2015,000,PIV15,Visit 15/Week 19,2011-09-27,196.0,08:50,08:51,-10.0,08:40,31200.0,-10.0,0.7,0.2317,0.70,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2015,000,PIV15,Visit 15/Week 19,2011-09-27,196.0,08:50,08:51,60.0,09:50,35400.0,59.0,1.82,0.60242,1.82,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2015,000,PIV15,Visit 15/Week 19,2011-09-27,196.0,08:50,08:51,90.0,10:20,37200.0,89.0,1.8,0.5958,1.80,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-14.0,09:50,09:52,120.0,11:50,42600.0,118.0,2.26,0.74806,2.26,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-14.0,09:50,09:52,150.0,12:20,44400.0,148.0,2.21,0.73151,2.21,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-03-13,364.0,10:00,10:02,-10.0,09:50,35400.0,-10.0,0.54,0.17874,0.54,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-14.0,09:50,09:52,-10.0,09:40,34800.0,-10.0,0.69,0.22839,0.69,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-14.0,09:50,09:52,0.0,09:50,35400.0,0.0,0.7,0.2317,0.70,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-14.0,09:50,09:52,15.0,10:05,36300.0,13.0,0.77,0.25487,0.77,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-14.0,09:50,09:52,30.0,10:20,37200.0,28.0,1.33,0.44023,1.33,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2011-07-12,119.0,08:10,08:10,-10.0,08:00,28800.0,-10.0,0.7,0.2317,0.70,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2011-07-12,119.0,08:10,08:10,0.0,08:10,29400.0,0.0,0.7,0.2317,0.70,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2011-07-12,119.0,08:10,08:10,15.0,08:25,30300.0,15.0,0.89,0.29459,0.89,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2011-07-12,119.0,08:10,08:10,30.0,08:40,31200.0,30.0,1.25,0.41375,1.25,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2011-07-12,119.0,08:10,08:10,60.0,09:10,33000.0,60.0,1.52,0.50312,1.52,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2011-07-12,119.0,08:10,08:10,90.0,09:40,34800.0,90.0,1.46,0.48326,1.46,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 14 (Week 8),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2014,000,PIV14,Visit 14/Week 8,2011-07-12,119.0,08:10,08:10,120.0,10:10,36600.0,120.0,2.12,0.70172,2.12,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 15 (Week 19),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2015,000,PIV15,Visit 15/Week 19,2011-09-27,196.0,08:50,08:51,120.0,10:50,39000.0,119.0,2.21,0.73151,2.21,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-14.0,09:50,09:52,240.0,13:50,49800.0,238.0,1.74,0.57594,1.74,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-03-13,364.0,10:00,10:02,0.0,10:00,36000.0,0.0,0.58,0.19198,0.58,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-03-13,364.0,10:00,10:02,15.0,10:15,36900.0,13.0,0.73,0.24163,0.73,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-03-13,364.0,10:00,10:02,30.0,10:30,37800.0,28.0,1.04,0.34424,1.04,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-03-13,364.0,10:00,10:02,60.0,11:00,39600.0,58.0,1.41,0.46671,1.41,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-03-13,364.0,10:00,10:02,90.0,11:30,41400.0,88.0,1.67,0.55277,1.67,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-03-13,364.0,10:00,10:02,120.0,12:00,43200.0,118.0,1.54,0.50974,1.54,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-03-13,364.0,10:00,10:02,150.0,12:30,45000.0,148.0,1.61,0.53291,1.61,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-03-13,364.0,10:00,10:02,180.0,13:00,46800.0,178.0,1.49,0.49319,1.49,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-03-13,364.0,10:00,10:02,210.0,13:30,48600.0,208.0,1.39,0.46009,1.39,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit 17 (Week 52),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,2017,000,PIV17,Visit 17/Week 52,2012-03-13,364.0,10:00,10:02,240.0,14:00,50400.0,238.0,1.3,0.4303,1.30,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-14.0,09:50,09:52,180.0,12:50,46200.0,178.0,2.2,0.7282,2.20,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
RETAIN_859067,SUB228883,Visit -1 (Week -1),ITN041AI,Part 1a,Adult,Alpha-1 Antitrypsin,2011-03-01,2011-03-01,-14.0,2010-12-14,-91.0,2011-03-15,Yes,2011-03-15,Yes,Yes,E/I/S,2011-03-15,2011-05-17,2011-04-19,2011-06-21,2012-06-12,2012-03-13,455.0,No,Terminated early from protocol,2013-03-19,735.0,Failure to Return/Lost to Follow-Up,Yes,2011-06-21,98.0,,23.0,Female,160.5,48.0,18.633359536,White,Multiple Races,Unknown,Terminated from study,1000,000,PIV-1,Visit -1/Week -1,2011-03-01,-14.0,09:50,09:52,210.0,13:20,48000.0,208.0,1.85,0.61235,1.85,NG/ML,pmol/mL,0.5 - 3.0,Normal,2014-01-31,,
